• SEC Filings

On October 10, 2017, MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with select accredited investors relating to the Company’s registered direct offering, issuance and sale (the “Offering”) of 769,231 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share. The purchase price per Share was $0.65. The Company has not engaged an underwriter or placement agent in connection with the Offering.

Proceeds from the Offering shall be used to continue clinical studies currently underway for the Company’s therapeutic antibodies and for working capital and general corporate purposes.

A copy of the form of Subscription Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K.

The net proceeds to the Company from the Offering, after deducting the Company’s estimated offering expenses, are expected to be approximately $470,000. The Offering is expected to close on or before October 12, 2017.

The Shares were issued to the Company’s previously filed and effective Registration Statement on Form S-3 that was filed with the Securities and Exchange Commission on July 14, 2017, as amended July 21, 2017, and declared effective July 27, 2017 (File No.333- 219291). The Company filed a prospectus supplement (“Prospectus Supplement”) related to the registered direct offering dated October 10, 2017.

The foregoing summaries of the terms of the Subscription Agreement are subject to, and qualified in their entirety by, such documents attached hereto as Exhibit 10.1, and incorporated herein by reference.

A copy of the opinion of Sichenzia Ross Friedman Ference LLPrelating to the validity of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.

MABVAX THERAPEUTICS HOLDINGS, INC. Exhibit
EX-5.1 2 ex5-1.htm OPINION exhibit 5.1   Exhibit 5.1     October 11,…
To view the full exhibit click here